Brown Rudnick represents Edwards Lifesciences in connection with its acquisition of Harpoon Medical
PUBLISHED ON: 12/07/2017
Brown Rudnick represented Edwards Lifesciences in connection with its acquisition of Harpoon Medical Inc., a privately held medical technology company pioneering beating-heart repair for degenerative mitral regurgitation. Under the terms of the merger agreement, Edwards paid $100 million in cash for Harpoon at closing on Dec. 1. In addition, there is the potential for up to $150 million in pre-specified milestone-driven payments over the next 10 years. In 2015, Brown Rudnick represented Edwards in connection with a structured upfront investment in Harpoon, with an exclusive option to acquire the company.
The Brown Rudnick team was led by partners Rob Funsten and Katy Gardner and included corporate associates Mary Ambacher and Jonathan Fitzsimons. Support for the transaction was provided by partner Adam Cantor and associate Stephanie Bollheimer (employee benefits), partner Vince Guglielmotti and associate Nicole Bouchard (tax), and partners Alan Kusinitz (antitrust) and Robert Tosti (intellectual property).
To read the press release issued by Edwards, please click here.
About Brown Rudnick LLP
Brown Rudnick’s Global Life Sciences M&A Group features a multi-disciplinary team of attorneys whose practices focus on serving companies and investors involved in the life sciences industry. Our team includes former corporate executives and in-house counsel from life sciences companies who work across practices and geographies to provide their holistic understanding of the industry to resolve complex transactions with strategic and practical solutions. Our dedicated understanding of the business and legal issues facing clients across the life sciences industry, contributed to daily by the needs of our extensive cliental, truly sets our practice apart from our competition.